The Association Between Attitudes and the Provision of Medications for Opioid Use Disorder (MOUD) in United States Jails

Overview

Journal Drug Alcohol Depend Rep

Specialty Psychiatry

Date 2024 Jan 11

PMID 38205144

Authors

Aly Pfaff

Amy Cochran

Jessi Vechinski

Todd Molfenter

Gabriel Zayas-Caban

Affiliations

Soon will be listed here.

Abstract

Background: Opioid use disorder is prevalent among individuals who are incarcerated, yet medications for opioid use disorder (MOUD) are not widely available in United States jails and prisons. Negative staff attitudes across the criminal legal system may prevent MOUD from being provided. We sought to determine if staff attitudes are associated with the provision of MOUD in prisons or jails.

Methods: 227 staff members of 43 jails and partnering community-based treatment providers answered questions on the effectiveness and acceptability of methadone, buprenorphine, and naltrexone. Response patterns were summarized with principal component analysis. Mixed-effects regression was performed to determine if attitudes toward MOUD were associated with the number of individuals screened and diagnosed with an OUD, referred to treatment, provided MOUD and referred to treatment after release.

Results: Sites whose staff had negative attitudes towards methadone and positive attitudes towards naltrexone were associated with fewer people being screened (Mean ratio [MR] = 0.84, 95 % CI: [0.72, 0.97]), diagnosed (MR = 0.85, 95 % CI: [0.73, 0.99]), referred (MR = 0.76, 95 % CI: [0.65, 0.89]), provided MOUD (MR = 0.70, 95 % CI: [0.58, 0.84]), and referred after release (MR = 0.82, 95 % CI: [0.72, 0.94]). Sites with overall positive attitudes towards all MOUD were associated with more people being screened (MR = 1.16, 95 % CI: [1.01, 1.34]), diagnosed (MR = 1.37, 95 % CI: [1.18, 1.60]), and referred to treatment (MR = 1.41, 95 % CI: [1.20, 1.65]).

Conclusions: Attitudinal barriers exist in the criminal legal system and are associated with the provision of MOUD.

References

Imai K, Keele L, Tingley D . A general approach to causal mediation analysis. Psychol Methods. 2010; 15(4):309-34. DOI: 10.1037/a0020761. View

Grella C, Ostile E, Scott C, Dennis M, Carnavale J . A Scoping Review of Barriers and Facilitators to Implementation of Medications for Treatment of Opioid Use Disorder within the Criminal Justice System. Int J Drug Policy. 2020; 81:102768. PMC: 8372195. DOI: 10.1016/j.drugpo.2020.102768. View

Moore K, Roberts W, Reid H, Smith K, Oberleitner L, McKee S . Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review. J Subst Abuse Treat. 2019; 99:32-43. PMC: 6391743. DOI: 10.1016/j.jsat.2018.12.003. View

Binswanger I, Stern M, Deyo R, Heagerty P, Cheadle A, Elmore J . Release from prison--a high risk of death for former inmates. N Engl J Med. 2007; 356(2):157-65. PMC: 2836121. DOI: 10.1056/NEJMsa064115. View

Molfenter T, Vechinski J, Taxman F, Breno A, Shaw C, Perez H . Fostering MOUD use in justice populations: Assessing the comparative effectiveness of two favored implementation strategies to increase MOUD use. J Subst Abuse Treat. 2021; 128:108370. PMC: 8384644. DOI: 10.1016/j.jsat.2021.108370. View

Joudrey P, Khan M, Wang E, Scheidell J, Edelman E, McInnes D . A conceptual model for understanding post-release opioid-related overdose risk. Addict Sci Clin Pract. 2019; 14(1):17. PMC: 6463640. DOI: 10.1186/s13722-019-0145-5. View

Martin R, Alexander-Scott N, Berk J, Carpenter R, Kang A, Hoadley A . Post-incarceration outcomes of a comprehensive statewide correctional MOUD program: a retrospective cohort study. Lancet Reg Health Am. 2023; 18:100419. PMC: 9950664. DOI: 10.1016/j.lana.2022.100419. View

Zaller N, McKenzie M, Friedmann P, Green T, McGowan S, Rich J . Initiation of buprenorphine during incarceration and retention in treatment upon release. J Subst Abuse Treat. 2013; 45(2):222-6. PMC: 3690138. DOI: 10.1016/j.jsat.2013.02.005. View

Binswanger I, Nowels C, Corsi K, Glanz J, Long J, Booth R . Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors. Addict Sci Clin Pract. 2012; 7:3. PMC: 3414824. DOI: 10.1186/1940-0640-7-3. View

10.

Kruis N, McLean K, Perry P . Exploring first responders' perceptions of medication for addiction treatment: Does stigma influence attitudes?. J Subst Abuse Treat. 2021; 131:108485. DOI: 10.1016/j.jsat.2021.108485. View

11.

Moore K, Siebert S, Kromash R, Owens M, Allen D . Negative attitudes about medications for opioid use disorder among criminal legal staff. Drug Alcohol Depend Rep. 2023; 3:100056. PMC: 9948914. DOI: 10.1016/j.dadr.2022.100056. View

12.

Evans E, Wilson D, Friedmann P . Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder. Drug Alcohol Depend. 2022; 231:109254. PMC: 8852331. DOI: 10.1016/j.drugalcdep.2021.109254. View

13.

Scott C, Grella C, Dennis M, Carnevale J, LaVallee R . Availability of best practices for opioid use disorder in jails and related training and resource needs: findings from a national interview study of jails in heavily impacted counties in the U.S. Health Justice. 2022; 10(1):36. PMC: 9763789. DOI: 10.1186/s40352-022-00197-3. View

14.

MacKinnon D, Lockwood C, Williams J . Confidence Limits for the Indirect Effect: Distribution of the Product and Resampling Methods. Multivariate Behav Res. 2010; 39(1):99. PMC: 2821115. DOI: 10.1207/s15327906mbr3901_4. View

15.

VanderWeele T, Vansteelandt S . Mediation Analysis with Multiple Mediators. Epidemiol Methods. 2015; 2(1):95-115. PMC: 4287269. DOI: 10.1515/em-2012-0010. View

16.

Cates L, Brown A . Medications for opioid use disorder during incarceration and post-release outcomes. Health Justice. 2023; 11(1):4. PMC: 9898706. DOI: 10.1186/s40352-023-00209-w. View

17.

Knudsen H, Ducharme L, Roman P, Link T . Buprenorphine diffusion: the attitudes of substance abuse treatment counselors. J Subst Abuse Treat. 2005; 29(2):95-106. DOI: 10.1016/j.jsat.2005.05.002. View

18.

Williams A, Nunes E, Bisaga A, Levin F, Olfson M . Development of a Cascade of Care for responding to the opioid epidemic. Am J Drug Alcohol Abuse. 2019; 45(1):1-10. PMC: 6404749. DOI: 10.1080/00952990.2018.1546862. View

19.

Rich J, McKenzie M, Larney S, Wong J, Tran L, Clarke J . Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet. 2015; 386(9991):350-9. PMC: 4522212. DOI: 10.1016/S0140-6736(14)62338-2. View

20.

Andraka-Christou B, Gabriel M, Madeira J, Silverman R . Court personnel attitudes towards medication-assisted treatment: A state-wide survey. J Subst Abuse Treat. 2019; 104:72-82. DOI: 10.1016/j.jsat.2019.06.011. View